News >

Guidelines Clarify Management of Immune-Related AEs in Lung Cancer

Danielle Bucco
Published: Wednesday, Mar 14, 2018

Heather Greene, NP

Heather Greene, NP
Immunotherapy has taken over the conversation for oncologists when discussing treatments for patients with lung cancer, explains Heather Greene, NP. The class of agents has been generally well tolerated in this patient population; however, there are adverse events (AEs) associated with this treatment strategy that require close monitoring, she adds.

State of the Science Summit™ on Advanced Non–Small Cell Lung Cancer, Greene, a nurse practitioner at West Cancer Center, discussed the safety profile for patients with lung cancer receiving immunotherapy, and the importance for reporting these immune-related AEs.

OncLive: Can you provide an overview of your presentation on the side effect profile of immunotherapy for patients with lung cancer?

Greene: Immunotherapy is an important conversation that oncologists are having. It is dominating the oncology world right now. From a nurse practitioner standpoint, we are on the frontlines and there are many important things that people should be aware of.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Advances in™ Therapies for Patients With ALK-Positive Lung Cancers: More Options…More Decisions…Better OutcomesAug 30, 20191.5
Oncology Briefings™: Treating Advanced NSCLC Without Actionable MutationsAug 30, 20191.0
Publication Bottom Border
Border Publication